Iradimed Co
$ 99.09
-1.92%
24 Feb - close price
- Market Cap 1,285,218,000 USD
- Current Price $ 99.09
- High / Low $ 101.22 / 98.79
- Stock P/E 57.73
- Book Value 7.43
- EPS 1.75
- Next Earning Report 2026-05-04
- Dividend Per Share $0.71
- Dividend Yield 0.69 %
- Next Dividend Date 2026-03-06
- ROA 0.16 %
- ROE 0.25 %
- 52 Week High 107.69
- 52 Week Low 46.79
About
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Analyst Target Price
$120.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-10-30 | 2025-08-01 | 2025-05-05 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-08 | 2023-11-03 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.54 | 0.47 | 0.49 | 0.37 | 0.4 | 0.43 | 0.42 | 0.36 | 0.39 | 0.43 | 0.36 | 0.3 |
| Estimated EPS | 0.465 | 0.46 | 0.44 | 0.38 | 0.41 | 0.39 | 0.37 | 0.34 | 0.4 | 0.36 | 0.31 | 0.28 |
| Surprise | 0.075 | 0.01 | 0.05 | -0.01 | -0.01 | 0.04 | 0.05 | 0.02 | -0.01 | 0.07 | 0.05 | 0.02 |
| Surprise Percentage | 16.129% | 2.1739% | 11.3636% | -2.6316% | -2.439% | 10.2564% | 13.5135% | 5.8824% | -2.5% | 19.4444% | 16.129% | 7.1429% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-04 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.45 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Nov 2025 | Aug 2025 | May 2025 | Mar 2025 | Nov 2024 | Aug 2024 | May 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-06 | 2025-12-30 | 2025-11-25 | 2025-08-28 | 2025-05-30 | 2025-03-05 | 2024-11-25 | 2024-08-30 | 2024-05-30 | 2024-01-12 |
| Amount | $0.2 | $0.5 | $0.17 | $0.17 | $0.17 | $0.17 | $0.15 | $0.15 | $0.15 | $0.63 |
Next Dividend Records
| Dividend per share (year): | $0.71 |
| Dividend Yield | 0.69% |
| Next Dividend Date | 2026-03-06 |
| Ex-Dividend Date | 2026-02-23 |
Recent News: IRMD
2026-02-18 12:57:46
Nine Ten Capital Management sold 342,907 shares of IRadimed (NASDAQ:IRMD), valued at an estimated $29.42 million, during the fourth quarter of 2025. Despite the sale, IRadimed's stock has risen 83% over the past year, reflecting its strong financial performance, including 18 consecutive quarters of record revenue and increased dividends. The fund's decision to trim its stake is attributed to portfolio discipline rather than a lack of confidence in the company's fundamentals, as it still represents 13.2% of their assets under management.
2026-02-16 01:57:13
Director Allen Monty K has sold 1,000 shares of IRADIMED (NASDAQ:IRMD) for a total of $100,256, with shares trading near their 52-week high and showing an 83.6% return over the past year. Despite a strong financial health rating and expected profitability, InvestingPro suggests the stock may be overvalued with a P/E ratio of 57.5. This transaction follows the company's impressive fourth-quarter 2025 earnings, which exceeded analyst expectations.
2026-02-14 02:52:00
Director Allen Monty K sold 1,000 shares of IRADIMED CORP (NASDAQ:IRMD) for $100,256 on February 13, 2026. This transaction occurred as the stock trades near its 52-week high and has shown an 83.6% return over the past year. Despite a P/E ratio of 57.5, suggesting potential overvaluation, the company recently reported strong fourth-quarter 2025 earnings, exceeding analyst expectations.
2026-02-14 00:57:39
Monty Allen, a Director at iRadimed Corp (IRMD), sold 1,000 shares of the company on February 13, 2026, reducing his holdings to 21,000 shares. This transaction follows a pattern of 26 insider sells and no buys over the past year. The stock is currently trading at $100.26, indicating it is significantly overvalued with a price-to-GF-Value ratio of 1.67 and a P/E ratio of 57.03 compared to an industry median of 28.48.
2026-02-13 23:57:39
IRADIMED (NasdaqGM:IRMD) announced its 18th consecutive quarter of record revenue and the full rollout of its 3870 MRI compatible IV infusion pump, alongside an increased quarterly dividend. The company has shown strong stock performance over the past five years, and the new pump is expected to drive further growth in Europe and Japan. While analysts see potential, Simply Wall St's valuation indicates the stock is currently trading significantly above its estimated fair value.
2026-02-13 23:04:46
IRADIMED (NasdaqGM:IRMD) announced an increased quarterly dividend to US$0.20 per share, following 18 consecutive quarters of record revenue and strong double-digit growth in sales and earnings. The company is experiencing robust adoption of its existing MRI-compatible devices and is shipping its new 3870 infusion pump, with management confident in future product launches and domestic replacement demand. While the dividend hike signals strong financial health, investors are advised to monitor the rollout and potential competitive pressures, especially given recent insider selling.
